Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 2 1

Status

Terminated 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Head & Neck 1Endocrine 1Dermatologic 1

Conditions

Thyroid Cancer, Papillary 1Melanoma 1

Interventions

Cyclophosphamide 910Carboplatin 788pembrolizumab 747Paclitaxel 744Bevacizumab 716Cisplatin 709Gemcitabine 621Docetaxel 584Rituximab 558Radiotherapy 548Dexamethasone 511Nivolumab 491Doxorubicin 445Fluorouracil 392Capecitabine 382Etoposide 358Pemetrexed 339Cytarabine 335Oxaliplatin 335Lenalidomide 328Prednisone 327Erlotinib Hydrochloride 323fludarabine phosphate 316Trastuzumab 305Leucovorin 299fludarabine 296Vincristine 288Bortezomib 284Filgrastim 284Cetuximab 277

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has results × Administration, Cutaneous × Clear all
NCT03850691 2024-01-17

Radiation and Combination Immunotherapy for Melanoma

Masonic Cancer Center, University of Minnesota

Phase 2 Completed
4 enrolled 11 charts
Dermatologic

Melanoma

NCT01974284 2019-11-25

Percutaneous Ethanol Injection for Primary Papillary Thyroid Microcarcinoma

Yale University

Phase NA Terminated
7 enrolled 4 charts
EndocrineHead & Neck

Thyroid Cancer, Papillary

Data powered by HemOnc (CC BY 4.0) Colophon âš¡